Secukinumab in the Management of Psoriatic Arthritis: Current Perspectives

Psoriatic arthritis (PsA) is a seronegative, inflammatory arthritis associated with cutaneous psoriasis. This disease is associated with significant morbidity, thus requiring early treatment initiation and reduction of disease activity. Anti-cytokine therapies are increasingly being used for the treatment of PsA. In addition to the anti-TNF agents, monoclonal antibodies targeting IL-17 have been approved for the treatment of PsA. Secukinumab is a monoclonal antibody against IL-17 and is currently approved for the management of PsA. In this literature-based review, the current status of secukinumab for the management of PsA is discussed.